OGN
Organon & Co.

1,412
Mkt Cap
$1.9B
Volume
2.84M
52W High
$16.08
52W Low
$6.18
PE Ratio
10.17
OGN Fundamentals
Price
$7.19
Prev Close
$7.29
Open
$7.10
50D MA
$7.94
Beta
0.88
Avg. Volume
6.75M
EPS (Annual)
$0.7171
P/B
2.52
Rev/Employee
$621,600.00
$10,095.68
Loading...
Loading...
News
all
press releases
OGN's VTAMA Cream Shows Sleep Benefits in Pediatric Atopic Dermatitis
Organon reports Phase 3 data showing VTAMA improved sleep in children as young as two with atopic dermatitis, reinforcing its dermatology push.
Zacks·7h ago
News Placeholder
More News
News Placeholder
Organon & Co. (NYSE:OGN) Receives Average Rating of "Reduce" from Brokerages
Shares of Organon & Co. (NYSE:OGN - Get Free Report) have earned a consensus rating of "Reduce" from the seven research firms that are covering the company, MarketBeat.com reports. Five research...
MarketBeat·10h ago
News Placeholder
New Analysis of Organons VTAMA (tapinarof) cream, 1%, Phase 3 Data Showed Early and Consistent Improvement in Patient-Reported Sleep Subdomains in Pediatric Patients Down to 2 Years of Age with Atopic Dermatitis
Organon (NYSE: OGN), a global healthcare company with a mission to deliver impactful medicines and solutions for a healthier every day, will present results from a sub-analysis of pooled data from...
Business Wire·3d ago
News Placeholder
Vanguard Group Inc. Has $383.72 Million Position in Organon & Co. $OGN
Vanguard Group Inc. raised its holdings in Organon & Co. (NYSE:OGN - Free Report) by 11.3% in the third quarter, according to its most recent Form 13F filing with the Securities & Exchange...
MarketBeat·3d ago
News Placeholder
Organon & Co. (NYSE:OGN) Trading Down 6.3% - Time to Sell?
Organon & Co. (NYSE:OGN) Shares Down 6.3% - Should You Sell...
MarketBeat·5d ago
News Placeholder
Organon & Co. (NYSE:OGN) Price Target Raised to $8.00 at Barclays
Barclays upped their price objective on Organon & Co. from $7.50 to $8.00 and gave the company an "underweight" rating in a report on Tuesday...
MarketBeat·6d ago
News Placeholder
Organon Enters into Agreement to License MIUDELLA, Sebela Pharmaceuticals Hormone-Free Intrauterine Device
Organon (NYSE: OGN), a global healthcare company with a mission to deliver impactful medicines and solutions for a healthier every day, announced today that it has entered into an agreement to...
Business Wire·8d ago
News Placeholder
Organon & Co. (NYSE:OGN) Shares Up 6.6% - What's Next?
Organon & Co. (NYSE:OGN) Trading Up 6.6% - Should You Buy...
MarketBeat·10d ago
News Placeholder
Ex-Dividend Reminder: Murphy USA, American States Water and Organon
Looking at the universe of stocks we cover at Dividend Channel, on 2/23/26, Murphy USA Inc (Symbol: MUSA), American States Water Co (Symbol: AWR), and Organon & Co (Symbol: OGN) will all trade...
Nasdaq News: Markets·11d ago
News Placeholder
Atopic Dermatitis Market to Accelerate at a Rapid Pace by 2034 with Advancements in Biologics and JAK Inhibitors DelveInsight
Atopic Dermatitis Market to Accelerate at a Rapid Pace by 2034 with Advancements in Biologics and JAK Inhibitors | DelveInsight Atopic Dermatitis Market to Accelerate at a Rapid Pace by 2034 with...
PR Newswire·14d ago
<
1
2
...
>

Latest OGN News

View
Top Discussions

Advertisement|Remove ads.

Advertisement|Remove ads.